Clinical Report: First Gaucher type 3 neurological drug approved
Overview
The FDA approved venglustat (Infilbray) for neurological symptoms of type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg. The approval was supported by a 52-week randomized trial in which the venglustat group improved on a combined neurological assessment compared with the enzyme replacement therapy group; the FDA announcement provided no numerical effect estimates.
Background
Gaucher disease is an inherited lysosomal storage disorder involving impaired breakdown of glucosphingolipids. GD3, unlike type 1 Gaucher disease, includes progressive neurological manifestations such as difficulties with balance, coordination, speech, memory, and cognition. Enzyme replacement therapy has been used for systemic manifestations, but the source describes venglustat as the first FDA-authorized treatment for GD3 neurological symptoms. Venglustat crosses the blood-brain barrier and inhibits glucosylceramide synthase.
Data Highlights
| Study or approval detail | Reported information |
|---|---|
| Trial design | Randomized, double-blind, multicenter clinical trial |
| Participants | 43 patients aged 12 years and older with GD3, previously treated with enzyme replacement therapy and with stable systemic disease |
| Treatment groups | Oral venglustat once daily or intravenous enzyme replacement therapy every 2 weeks |
| Study duration | 52 weeks |
| Efficacy assessment | Two measures of neurological manifestations, including ataxia and cognitive function |
| Week 52 result | The venglustat group improved on a combined neurological assessment compared with the enzyme replacement therapy group; numerical treatment-effect estimates were not provided in the FDA announcement |
| Approved population | Adults and pediatric patients weighing at least 15 kg |
Key Findings
- The FDA approved venglustat (Infilbray) as the first treatment authorized for neurological symptoms of GD3.
- The indication covers adults and pediatric patients weighing at least 15 kg.
- Venglustat is an oral glucosylceramide synthase inhibitor that crosses the blood-brain barrier and reduces glucosphingolipid accumulation in the body and brain.
- The supporting trial enrolled 43 patients aged 12 years and older who had received enzyme replacement therapy and achieved stable systemic disease.
- At week 52, patients receiving venglustat improved on a combined neurological assessment compared with those receiving enzyme replacement therapy; the FDA announcement did not report numerical estimates.
- Frequently reported adverse effects included gastrointestinal symptoms and mood-related changes. Serious psychiatric risks, including suicidal ideation and behavior, were reported; animal studies identified potential visual-clouding risks in younger patients and adverse fetal-development effects with pregnancy exposure.
Clinical Implications
The approval provides an FDA-authorized treatment specifically for neurological symptoms of GD3, while the trial compared venglustat with enzyme replacement therapy in patients whose systemic disease was stable. The source reports gastrointestinal and mood-related adverse effects, serious psychiatric risks, and potential risks identified in animal studies; these safety findings are relevant to clinical use.
Conclusion
Venglustat is the first FDA-approved therapy for neurological symptoms of GD3 in eligible adults and pediatric patients. Its approval was based on a 52-week trial showing improvement on a combined neurological assessment, with no numerical effect estimates provided in the FDA announcement.
Related Resources & Content
- U.S. Food and Drug Administration, FDA, 2026 -- FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
- French national diagnosis and care protocol, Orphanet Journal of Rare Diseases, 2025 -- Gaucher disease
- MDSpire News -- FDA OKs First Niemann-Pick Type C Drug
- The Medicine Maker -- FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
- MDSpire News -- FDA approves therapy for GSDIa
- mdspire news — FDA approves gene therapy for MPS IIIA
- FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
- French national diagnosis and care protocol: Gaucher disease
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
